Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharm Biopharm ; 95(Pt B): 271-8, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25592326

ABSTRACT

Silk hydrogels were formulated with anti-vascular endothelial growth factor (anti-VEGF) therapeutics for sustained ocular drug delivery. Using silk fibroin as a vehicle for delivery, bevacizumab-loaded hydrogel formulations demonstrated sustained release of 3 months or greater in experiments in vitro as well as in vivo using an intravitreal injection model in Dutch-belted rabbits. Using both standard dose (1.25mg bevacizumab/50 µL injection) and high dose (5.0mg bevacizumab/50 µL injection) hydrogel formulations, release concentrations were achieved at day 90 that were equivalent or greater than those achieved at day 30 with the positive standard dose control (single injection (50 µL) of 1.25mg bevacizumab solution), which is estimated to be the therapeutic threshold based on the current dosage administration schedule of 1 injection/month. These gels also demonstrated signs of biodegradation after 3 months, suggesting that repeated injections may be possible (e.g., one injection every 3-6 months or longer). Due to its pharmacokinetic and biodegradation profiles, this delivery system may be used to reduce the frequency of dosing for patients currently enduring treatment using bevacizumab or other anti-VEGF therapeutics.


Subject(s)
Angiogenesis Inhibitors/administration & dosage , Bevacizumab/administration & dosage , Drug Delivery Systems , Fibroins/chemistry , Administration, Ophthalmic , Angiogenesis Inhibitors/pharmacokinetics , Angiogenesis Inhibitors/pharmacology , Animals , Bevacizumab/pharmacokinetics , Bevacizumab/pharmacology , Delayed-Action Preparations , Dose-Response Relationship, Drug , Drug Liberation , Hydrogels , Intravitreal Injections , Rabbits , Silk/chemistry , Time Factors , Vascular Endothelial Growth Factor A/antagonists & inhibitors
2.
Anal Chem ; 85(3): 1932-9, 2013 Feb 05.
Article in English | MEDLINE | ID: mdl-23331316

ABSTRACT

We report a method for the sensitive measurement of genomic DNA based on the direct detection of single molecules of DNA in arrays of femtoliter wells. The method begins by generating short fragments of DNA from large, double-stranded molecules of genomic DNA using either restriction enzymes or sonication. Single-stranded fragments are then generated by melting the duplex, and these fragments are hybridized to complementary biotinylated detection probes and capture probes on paramagnetic beads. The resulting DNA complexes are then labeled with an enzyme (streptavidin-ß-galactosidase), and single enzymes associated with these complexes on beads are detected in single molecule arrays (Simoa). DNA concentration is quantified by determining the average number of enzymes per bead via Poisson statistics (digital) or the average bead intensity (analog). The Simoa DNA assay was used to detect genomic DNA purified from S. aureus with an average limit of detection (LOD) of 0.07 fM, or 2100 DNA molecules per 50 µL sample. We used this assay to detect S. aureus spiked into (a) whole blood, with an average LOD of 1100 bacteria per 25 µL sample (0.074 fM), and (b) water from the Charles River, with an LOD of 1300 bacteria per 50 µL sample (0.042 fM). Bacteria were detected in river water without prior purification of DNA. The Simoa DNA assay, which directly detects target DNA molecules without molecular replication, is an attractive alternative to existing sensitive DNA detection technologies that rely on amplification using polymerases, such as the polymerase chain reaction (PCR).


Subject(s)
DNA, Bacterial/analysis , Genome, Bacterial , Nanotechnology/methods , Oligonucleotide Array Sequence Analysis/methods , Genome, Bacterial/genetics , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...